文献速递癫痫神经免疫

LGI1抗体脑炎相关癫痫的临床病程与特征

Clinical Course and Features of Seizures Associated With LGI1-Antibody Encephalitis.
PubMed 文献 · Neurology · 2021-07-07

本研究基于Mayo Clinic电子病历和神经免疫实验室记录,纳入49例LGI1抗体脑炎相关癫痫患者,随访至少24个月。结果显示20.4%患者发展为慢性癫痫,女性(p=0.048)和发病年龄较轻(p=0.02)是危险因素;40.8%患者出现复发,中位首次复发时间7.5个月,初始长期免激素免疫治疗与较低复发风险相关(HR 0.28,95%CI 0.11-0.73,p=0.009)。

要点

  • LGI1抗体脑炎相关癫痫患者中20.4%发展为慢性癫痫
  • 女性及发病年龄较轻与慢性癫痫风险相关
  • 长期免激素免疫治疗可降低复发风险(HR 0.28)

核心结论

  • 尽管积极免疫治疗,20.4%的LGI1抗体脑炎患者仍发展为慢性癫痫。
  • 女性及发病年龄较轻是慢性癫痫的危险因素。
  • 长期免激素免疫治疗与较低复发风险相关。

研究设计与样本

  • 回顾性队列研究,纳入Mayo Clinic电子病历及神经免疫实验室记录的49例LGI1抗体脑炎相关癫痫患者,随访至少24个月。
  • 采用二元逻辑回归分析慢性癫痫预测因素,单因素Cox比例风险回归分析复发风险。

主要发现

  • 49例患者中48例(98%)接受免疫治疗,末次随访时10例(20.4%)诊断为明确或可能的慢性癫痫。
  • 20例(40.8%)出现复发,中位首次复发时间7.5个月(范围3-94个月)。
  • 女性(p=0.048)和发病年龄较轻(p=0.02)与慢性癫痫发展相关。
  • 初始长期免激素免疫治疗与复发风险降低相关(HR 0.28,95%CI 0.11-0.73,p=0.009)。

临床怎么用

  • 对LGI1抗体脑炎相关癫痫患者应关注女性及年轻发病者,警惕慢性癫痫风险。
  • 考虑初始即采用长期免激素免疫治疗以降低复发风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: To determine risk factors associated with clinical relapses and development of chronic epilepsy in patients with anti-leucine-rich glioma-inactivated 1 (LGI1) immunoglobulin G encephalitis. METHODS: Patients with seizures related to LGI1-antibody encephalitis with ≥24 months of follow-up from disease onset were identified in the Mayo Clinic electronic medical record and neuroimmunology laboratory records. Charts were reviewed to determine clinical factors, seizure types, imaging, treatment, occurrence of relapse, and outcome. Binary logistic regression analysis was performed to identify predictors of the development of chronic epilepsy. Univariate Cox proportional hazards regression was used to examine the influence of baseline characteristics on relapse risk. RESULTS: Forty-nine patients with LGI1-antibody encephalitis and acute symptomatic seizures were identified. Almost all patients (n = 48, 98%) were treated with immunotherapy. Eight had definite and 2 had possible chronic epilepsy at the last follow-up (10 of 49, 20.4%). Female sex (p = 0.048) and younger age at disease onset (p = 0.02) were associated with development of chronic epilepsy. Relapses occurred in 20 (40.8%), with a median time to first relapse of 7.5 months (range 3-94 months). Initial treatment with long-term steroid-sparing immunotherapy was associated with reduced risk of relapse (hazard ratio 0.28, 95% confidence interval 0.11-0.73, p = 0.009). DISCUSSION: Chronic epilepsy occurred in 20.4% of our patients with LGI1-antibody encephalitis despite aggressive immunotherapy. Risk factors for chronic epilepsy were female sex and earlier age at onset. Relapses occurred in 40.8% of patients with prolonged follow-up, and long-term steroid-sparing immunotherapy was associated with a lower relapse rate.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Smith KM, Dubey D, Liebo GB, et al. Clinical Course and Features of Seizures Associated With LGI1-Antibody Encephalitis. Neurology. 2021. PMID: 34233939. doi:10.1212/WNL.0000000000012465

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。